Ipsen Canada Appoints Ed Dybka as General Manager

 Mississauga, ON – October 11, 2018 – Ipsen Biopharmaceuticals Canada Inc., an affiliate of Ipsen (Euronext: IPN; ADR: IPSEY), today announced the appointment of Ed Dybka as General

Manager, effective October 15. Mr. Dybka will oversee Ipsen Biopharmaceuticals Canada’s operations across all therapeutic areas and report directly to Richard Paulson, CEO, Ipsen North America. Mr. Dybka will also be a member of the Ipsen North America Leadership Team.

Mr. Dybka brings to Ipsen a wealth of experience and over 30 years in the pharmaceutical industry within the Canadian market. Most recently, he led the development of an early stage biotech company as a joint venture between Mars Innovation (Toronto) and The Center for Drug Research and Development (Vancouver).

“We are delighted to welcome Ed to Ipsen Canada as we establish new milestones on our path to maintaining strong growth and further expanding our relationships with researchers and organizations across the Canadian healthcare ecosystem,” noted Richard Paulson, CEO, Ipsen North America. “Ed brings a wealth of leadership expertise, a track record of fostering innovation, and an in-depth understanding of our industry garnered from his extensive work within the Canadian pharmaceutical market. He is a valuable addition to the Ipsen Canada team.”

Prior to his work with Mars Innovation, Mr. Dybka was President and CEO of AstraZeneca Canada Inc., and formerly led the Canadian establishment of Almirall, a start-up biopharmaceutical company focused on the treatment of respiratory diseases. Mr. Dybka also held a number of executive roles at GlaxoSmithKline Canada including Vice President of Marketing, Sales and Public Affairs & Reimbursement. Earlier in his career at GlaxoSmithKline he held progressively more senior roles in sales and marketing.

Ed Dybka added: “I am honored to be joining Ipsen Canada at such a transformational time in the company’s history and look forward to working on achieving its mission of improving patients’ lives. Throughout my career, I have taken great pride in knowing that the work our industry does directly improves the lives of millions of patients across Canada.”

Mr. Dybka is currently Vice-Chair of the board of Life Sciences Ontario and a Director on the board of Clinical Trials Ontario. He is Vice-Chair of the Health & Biosciences Economic Strategy Table for the Federal Ministry of Health and Ministry of Innovation, Science and Economic Development, which recently published a set of foundational recommendations for the advancement of the Health & Biosciences sector in Canada.

Mr. Dybka succeeds Paul Reider, who leaves Ipsen Canada to pursue other opportunities after three years with the organization, most recently as the General Manager for Ipsen Canada, where he led the organization through a number of Health Canada approvals bringing new innovation to patients with difficult-to-treat diseases.

“Paul has been an instrumental team member and I’d like to thank him for his many contributions and unwavering commitment to the business over the last few years. I wish him well in his new endeavors,” commented Paulson.


About Ipsen

Ipsen Biopharmaceuticals Canada Inc., the Canadian affiliate of Ipsen, is headquartered in Mississauga, Ontario, with established operations since October 2015. For more information on Ipsen Biopharmaceuticals Canada Inc. visit www.ipsen.ca. Ipsen is a global specialty-driven biopharmaceutical group focused on innovation and specialty care. The group develops and commercializes innovative medicines in three key therapeutic areas – Oncology, Neuroscience and Rare Diseases. Its commitment to Oncology is exemplified through its growing portfolio of key therapies for prostate cancer, neuroendocrine tumors, renal cell carcinoma and pancreatic cancer. Ipsen’s R&D is focused on its innovative and differentiated technological platforms located in the heart of the leading biotechnological and life sciences hubs (Paris-Saclay, France; Oxford, UK; Cambridge, US). The Group has about 5,400 employees worldwide. Ipsen is listed in Paris (Euronext: IPN) and in the United States through a Sponsored Level I American Depositary Receipt program (ADR: IPSEY). For more information on Ipsen, visit www.ipsen.com.


For further information: 

Diana Robson                                                                    Marisol Peron

Proof Inc.                                                                           Ipsen Biopharmaceuticals

drobson@getproof.com                                                  marisol.peron@ipsen.com

(416) 969-2815                                                                 (908) 275 6330


©2024 Ipsen Biopharmaceuticals, Inc. All rights reserved. June 2023 CR-CA-000013